Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Dr. Reddy's Laboratories Ltd Common Stock (RDY) Price & Performance

Inovio Pharmaceuticals IncTrade
Dr. Reddy's Laboratories Ltd Common StockTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.98 (market cap $101.95M), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 104.1× Inovio Pharmaceuticals Inc's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.

INORDY
Market Cap
$101.95M$10.61B
Volume
2,985,8473,738,869
Sector
HealthHealth
52-Week High
$2.60$15.38
52-Week Low
$0.66$11.38
Typical Hold Time
43 Days0 Days
Enterprise Value
$73.28M$10.51B
Dividend Yield
—0.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 but has beaten EPS estimates for three consecutive quarters. Key focus remains on the FDA's October 30, 2026 PDUFA decision for INO-3107, its lead candidate for recurrent respiratory papillomatosis. Analyst consensus is bullish with a $2.75 price target, though financials reveal significant losses with a -130,000% net income margin and negative cash flow from operations.

The investment case hinges on regulatory approval of INO-3107, offering substantial upside if successful. However, high cash burn, persistent losses, and dependence on financing pose severe risks. With 59% of analysts rating Buy, the stock presents a high-risk, high-reward opportunity suitable only for speculative investors comfortable with binary outcomes.

Dr. Reddy's Laboratories Ltd Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
97% Buy3% Sell
Avg holding period · 43 Days
RDY
100% Buy0% Sell
Avg holding period · 0 Days

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About Dr. Reddy's Laboratories Ltd Common Stock

Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.

Read more on RDY →